Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT)

International Journal of Cancer

Volumn 119, Issue 4, 2006, Pages 750-756

  Hoebers, Frank J P ^a   Pluim, Dick ^a   Verheij, Marcel ^a   Balm, Alfons J M ^a,b   Bartelink, Harry ^a   Schellens, Jan H M ^a,c   Begg, Adrian C ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Chemoradiation; Cisplatin; DNA adducts; Head and neck cancer

Indexed keywords

ADENOSINE; ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; GUANOSINE; PHOSPHORUS 32; SEROTONIN 3 ANTAGONIST; SODIUM THIOSULFATE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CHEEK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA ADDUCT; DOSE RESPONSE; DYSPHAGIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LEUKOCYTE; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA ADDUCTS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745924971     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21919     Document Type: Article

References (33)

1. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55.
2. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre J, Greiner R, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
3. Cooper J, Pajak T, Forastiere A, Jacobs J, Campbell B, Saxman S, Kish J, Kim H, Cmelak A, Rotman M, Machtay M, Ensley J, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
4. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.
5. Schaake-Koning C, van den BW, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
6. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, III, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
7. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
8. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
9. Thomas GM. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340:1198-200.
10. Robbins KT, Kumar P, Regine WF, Wong FS, Weir AB, III, Flick P, Kun LE, Palmer R, Murry T, Fontanesi J, Ferguson R, Thomas R, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys 1997;38:263-71.
11. Robbins KT, Kumar P, Wong FS, Hartsell WF, Flick P, Palmer R, Weir AB, III, Neill HB, Murry T, Ferguson R, Hanchett C, Vieira F, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 2000;22:687-93.
12. Balm AJ, Rasch CR, Schornagel JH, Hilgers FJ, Keus RB, Schultze-Kool L, Ackerstaff AH, Busschers W, Tan IB. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 2004;26:485-93.
13. Bartelink H, Kallman RF, Rapacchietta D, Hart GA. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiother Oncol 1986;6:61-74.
14. Begg AC, van der Kolk PJ, Dewit L, Bartelink H. Radiosensitization by cisplatin of RIF1 tumour cells in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1986;50:871-84.
15. Fichtinger-Schepman AM, van Oosterom AT, Lohman PH, Berends F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 1987;47:3000-4.
16. Terheggen PM, Emondt JY, Floot BG, Dijkman R, Schrier PI, den Engelse L, Begg AC. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res 1990;50:3556-61.
17. Blommaert FA, Michael C, Terheggen PM, Muggia FM, Kortes V, Schornagel JH, Hart AA, den Engelse L. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 1993;53:5669-75.
18. Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, Boer-Dennert M, Schmitz PI, Stoter G, Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996;73:1569-75.
19. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987;84:5024-8.
20. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, Begg AC. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000;89:160-6.
21. Ma J, Verweij J, Planting AS, Boer-Dennert M, van Ingen HE, van der Burg ME, Stoter G, Schellens JH. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer 1995;71:512-7.
22. 32P-postlabeling assay for the quantification of the major platinum-DNA adducts. Anal Biochem 1999;275:30-8.
23. Moses BL, Chan DW, Hruban RH, Forastiere A, Richtsmeier WJ. Comparison of intra-arterial and intravenous infusion of cisplatin for head and neck squamous cell carcinoma in a modified rat model. Arch Otolaryngol Head Neck Surg 1993;119:612-7.
24. Gouyette A, Apchin A, Foka M, Richard JM. Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur J Cancer Clin Oncol 1986;22:257-63.
25. Los G, Blommaert F, Barton R, Heath DD, den Engelse L, Hanchett C, Vicario D, Weisman R, Robbins KT, Howell SB. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemother Pharmacol 1995;37(1/2):150-4.
26. Sileni VC, Fosser V, Maggian P, Padula E, Beltrame M, Nicolini M, Arslan P. Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. Cancer Chemother Pharmacol 1992;30:221-5.
27. Tegeder I, Brautigam L, Seegel M, Al Dam A, Turowski B, Geisslinger G, Kovacs AF. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther 2003;73:417-26.
28. Hecquet B, Vennin P, Fournier C, Poissonnier B. Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer. Cancer Res 1987;47:6134-7.
29. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Itamochi H, Cheng X, Okada M, Terakawa N. Clinical responses and platinum concentrations in tumors after intra-arterial and intravenous administration of cisplatin in the same patients with cervical cancer. Gynecol Obstet Invest 1997;44:57-60.
30. Lagrange JL, Bondiau PY, Tessier E, Chauvel P, Renee N, Etienne MC, Milano G. Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer. Int J Cancer 1996;68:452-6.
31. Jakowatz JG, Ginn GE, Snyder LM, Dieffenbach KW, Wile AG. Increased cisplatin tissue levels with prolonged arterial infusion in the rat. Cancer 1991;67:2828-32.
32. Fichtinger-Schepman AM, van der Velde-Visser SD, Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, Berends F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990;50:7887-94.
33. Crul M, Schoemaker NE, Pluim D, Maliepaard M, Underberg RW, Schot M, Sparidans RW, Baas P, Beijnen JH, van Zandwijk N, Schellens JH. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003;9:3526-33.